A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of NNC0487 in Subjects with Hepatic Impairment and Normal Hepatic Function

The primary objective is to evaluate the pharmacokinetics of NNC0487 0111 in subjects with hepatic impairment compared to those with normal liver function. Determining blood levels of the medicinal product in this population is clinically relevant to assess how impaired liver function affects the systemic exposure of the compound. The secondary objective is to assess the safety and tolerability of the study drug in these subjects.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers and patients, including both males and females. The participants fall within the age category represented by code 3. Individuals with hepatic impairment are identified as a relevant medical condition within the study population.

This Phase 3 clinical trial is designed to evaluate the pharmacokinetics and tolerability of the investigational medicinal product NNC0487 0111 in individuals with hepatic impairment and those with normal liver function. The study methodology involves a sequence of scheduled assessments beginning with a screening visit to determine eligibility. Following enrollment, participants will undergo periodic follow-up visits to monitor blood levels of the study drug and assess safety parameters. The protocol concludes with an end-of-study visit. The total duration of participant involvement is determined by the specific assessment schedule, and early termination may occur based on predefined safety or clinical criteria.

The assessment of efficacy in this Phase 3 clinical trial for hepatic impairment is not specified in the provided documentation.